NYSE: CRLCharles River Laboratories International Inc Stock
$227.81-11.62 (-4.85%)
Updated Apr 25, 2024
CRL Price
$227.81
Fair Value Price
N/A
Market Cap
$11.70B
52 Week Low
$161.65
52 Week High
$275.00
P/E
24.57x
P/B
3.25x
P/S
2.93x
PEG
0.57x
Dividend Yield
N/A
Revenue
$4.13B
Earnings
$474.62M
Gross Margin
36.4%
Operating Margin
17.25%
Profit Margin
11.5%
Debt to Equity
1.26
Operating Cash Flow
$684M
Beta
1.17
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CRL Overview
Charles River Laboratories International, Inc. offers a variety of preclinical and clinical laboratory, gene therapy, and cell therapy services to the Pharmaceutical, Medical Device, and Biotechnology sectors. Charles River was founded in 1947 and is headquartered in Wilmington, MA.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CRL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRL ($227.81) is trading above its intrinsic value of $189.58, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRL is good value based on its earnings relative to its share price (24.57x), compared to the US market average (40.97x)
P/E vs Market Valuation
CRL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more CRL due diligence checks available for Premium users.
Be the first to know about important CRL news, forecast changes, insider trades & much more!
CRL News
Valuation
CRL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
24.57x
Industry
38.32x
Market
40.97x
CRL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CRL is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CRL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.25x
Industry
4.15x
CRL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRL price to earnings growth (PEG)
For valuing profitable companies with growth potential
CRL is good value based... subscribe to Premium to read more.
PEG Value Valuation
CRL's financial health
Profit margin
Revenue
$1.0B
Net Income
$187.1M
Profit Margin
18.5%
CRL's Earnings (EBIT) of $712.25M... subscribe to Premium to read more.
Interest Coverage Financials
CRL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.2B
Liabilities
$4.5B
Debt to equity
1.26
CRL's short-term assets ($1.61B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRL's long-term liabilities ($3.48B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$220.9M
Investing
-$238.4M
Financing
$123.6M
CRL's operating cash flow ($683.90M)... subscribe to Premium to read more.
Debt Coverage Financials
CRL vs Diagnostic & Research Stocks
Charles River Laboratories International Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.